echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Announcement of the State Food and Drug Administration on the conversion of Beiqi tablets into over-the-counter drugs (No. 14 of 2021)

    Announcement of the State Food and Drug Administration on the conversion of Beiqi tablets into over-the-counter drugs (No. 14 of 2021)

    • Last Update: 2021-07-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    According to the "Administrative Measures for the Classification of Prescription Drugs and Over-the-Counter Drugs (Trial)" (formerly State Drug Administration Order No.
    10), Beiqi tablets have been transformed from prescription drugs into non-prescription drugs after the State Drug Administration organized demonstration and approval
    .


    The list of varieties (Annex 1) and the template of non-prescription drug instructions (Annex 2) are released together


    Before April 17, 2021, the holder of the drug marketing authorization shall submit the revised drug insert sheet to the provincial drug regulatory authority for the record in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations, and promptly notify the relevant medical institutions, Units such as pharmaceutical business enterprises
    .

    The contents of the non-prescription drug inserts other than those specified in the template inserts shall be implemented in accordance with the original approval documents
    .


    If the drug label involves related content, it should be revised together


    Hereby announce
    .


    Attachment: 1.


    List of varieties

    2.
    Templates for non-prescription drug instructions




    State Food and Drug Administration

    January 18, 2021

    Announcement No.


    14 of 2021 Annex 1.
    doc of the National Medical Products Administration

    Announcement No.


    14 of 2021 Annex 2 of the National Medical Products Administration.




    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.